The Manufacturers Life Insurance Company Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

The Manufacturers Life Insurance Company grew its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 40.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 299,152 shares of the biotechnology company’s stock after buying an additional 86,571 shares during the period. The Manufacturers Life Insurance Company owned 0.14% of BioCryst Pharmaceuticals worth $2,274,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. CWM LLC increased its stake in shares of BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC grew its stake in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,599 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,322 shares during the last quarter. nVerses Capital LLC bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at $63,000. Finally, DRW Securities LLC bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at about $74,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $7.61 on Monday. The stock has a fifty day moving average of $7.58 and a 200 day moving average of $7.35. The stock has a market cap of $1.58 billion, a PE ratio of -12.48 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter last year, the firm posted ($0.19) earnings per share. The company’s revenue was up 35.1% compared to the same quarter last year. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on BCRX shares. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.